Evaluation of the efficacy and safety of pregabalin, venlafaxine, and carbamazepine in patients with painful diabetic peripheral neuropathy. A randomized, double-blind trial

Nazanin Razazian, Maryam Baziyar, Nasrin Moradian, Daryoush Afshari, Arash Bostani, Marziyeh Mahmoodi, Nazanin Razazian, Maryam Baziyar, Nasrin Moradian, Daryoush Afshari, Arash Bostani, Marziyeh Mahmoodi

Abstract

Objective: To evaluate the efficacy and safety of carbamazepine, pregabalin, and venlafaxine in patients with painful diabetic neuropathy (PDN).

Methods: Our study was performed as a randomized, double-blind, parallel-group clinical trial between December 2012 and December 2013 at Kermanshah University of Medical Sciences, Kermanshah, Iran. Two hundred and fifty-seven patients with clinically definite PDN were randomized to receive, carbamazepine, venlafaxine, or pregabalin. The primary outcome was subjective pain as assessed by the visual analogue scale (VAS). Secondary outcomes consisted of sleep, mood, and work interference assessments, and a percentage of patients achieving at least 50% reduction in pain intensity.

Results: Means of VAS scores for carbamazepine, pregabalin, and venlafaxine treatment groups at the baseline (74.5, 82.3, and 74.5) and endpoint (39.6, 33.4, and 46.6) revealed significant reduction, although pregabalin was more efficacious than carbamazepine, and venlafaxine. Improvements in means scores of sleep, mood, and work interferences were identified in all treatment groups.

Conclusion: This study showed the efficacy of venlafaxine, pregabalin, and carbamazepine in pain reduction in patients with diabetic neuropathy, although pregabalin was shown to be superior to carbamazepine, and venlafaxine in relieving pain, no significant superiority was shown between carbamazepine, and venlafaxine.

Figures

Figure 1
Figure 1
Distribution of diabetic peripheral neuropathy patients. Ec/MoH - European Commission/Ministry of Health
Figure 2
Figure 2
Comparisons of pain severity scores (VAS) between the treatment groups across time among diabetic peripheral neuropathy patients.
Figure 3
Figure 3
Change in pain severity in the treatment groups among diabetic peripheral neuropathy patients. Improved and worse categories includes cases with VAS reduction and increase. VAS - visual analogue scale

References

    1. Apfel SC, Asbury AK, Bril V, Burns TM, Campbell JN, Chalk CH, et al. Positive neuropathic sensory symptoms as endpoints in diabetic neuropathy trials. J Neurol Sci. 2001;189:3–5.
    1. Abbott CA, Malik RA, van Ross ER, Kulkarni J, Boulton AJ. Prevalence and characteristics of painful diabetic neuropathy in a large community-based diabetic population in the U.K. Diabetes Care. 2011;34:2220–2224.
    1. Davies M, Brophy S, Williams R, Taylor A. The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes. Diabetes Care. 2006;29:1518–1522.
    1. Backonja MM, Serra J. Pharmacological management part 1: better-studied neuropathic pain diseases. Pain Med. 2004;5(Suppl 1):28–47. Review.
    1. Boulton AJ, Vinik AI, Arezzo JC, Bril V, Feldman EL, Freedman R, et al. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care. 2005;28:956–962.
    1. Gordois A, Scuffham P, Shearer A, Oglesby A, Tobian JA. The health care costs of diabetic peripheral neuropathy in the US. Diabetes Care. 2003;26:1790–1795.
    1. Jia HY, Li QF, Song PD, AN ZM, Liu YP, Ran XW, et al. Effect of venlafaxine and carbamazepine for painful peripheral diabetic neuropathy: A randomized, double-blind and double-dummy, controlled multi-center trial. Chin J Evid Based Med. 2006;6:321–327.
    1. Devi P, Madhu K, Ganapathy B, Sarma G, John L, Kulkarni C. Evaluation of efficacy and safety of gabapentin, duloxetine, and pregabalin in patients with painful diabetic peripheral neuropathy. Indian J Pharmacol. 2012;44:51–56.
    1. Leibson CL, Williamson DF, Melton LJ, 3rd, Palumbo PJ, Smith SA, Ransom JE, et al. Temporal trends in BMI among adults with diabetes. Diabetes Care. 2001;24:1584–1589.
    1. Smith HS, Argoff CE. Pharmacological treatment of diabetic neuropathic pain. Drugs. 2011;71:557–589.
    1. Kamei J, Mizoguchi H, Narita M, Tseng LF. Therapeutic potential of PKC inhibitors in painful diabetic neuropathy. Expert Opin Investig Drugs. 2001;10:1653–1664.
    1. Habib AA, Brannagan TH., 3rd Therapeutic strategies for diabetic neuropathy. Curr Neurol Neurosci Rep. 2010;10:92–100.
    1. Chong MS, Hester J. Diabetic painful neuropathy: current and future treatment options. Drugs. 2007;67:569–585.
    1. Boulton AJ, Malik RA, Arezzo JC, Sosenko JM. Diabetic somatic neuropathies. Diabetes Care. 2004;27:1458–1486.
    1. Reips UD, Funke F. Interval-level measurement with visual analogue scales in internet based research: VAS Generator. Behavior Res Methods. 2008;40:699–704.
    1. Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain. 2008;9:105–121.
    1. Hurley RW, Lesley MR, Adams MC, Brummett CM, Wu CL. Pregabalin as a treatment for painful diabetic peripheral neuropathy: a meta-analysis. Reg Anesth Pain Med. 2008;33:389–394.
    1. Bril V, England J, Franklin GM, Backonja M, Cohen J, Del Toro D, et al. Evidence-based guideline: Treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology. 2011;76:1786–1765.
    1. Rowbotham MC, Goli V, Kunz NR, Lei D. Venlafaxine extended release in treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain. 2004;110:697–706.
    1. Simpson DA. Gabapentin and venlafaxine for the treatment of painful diabetic neuropathy. J Clin Neuromuscular Dis. 2001;3:53–62.
    1. Lindsay TJ, Rodgers BC, Savath V, Hettinger K. Treating diabetic peripheral neuropathic pain. Am Fam Physician. 2010;82:151–158.
    1. Chakrabarti AK, Samantary SK. Diabetic peripheral neuropathy: nerve conduction studies before, during and after carbamazepine therapy. Aust N Z J Med. 1976;6:565–568.
    1. Lesser H, Sharma U, LaMoreaux L, Poole RM. Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology. 2004;63:2104–2110.
    1. Richter RW, Portenoy R, Sharma U, Lamoreaux L, Bockbrader H, Knapp LE. Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. J Pain. 2005;6:253–260.
    1. Rosenstock J, Tuchman M, LaMoreaux L, Sharma U. Pregabalin for treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain. 2004;110:628–638.
    1. Freynhagen R, Strojek K, Griesing T, Whalen E, Balkennohl M. Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomized, double-blind, multicenter, placebo-controlled trials of flexible and fixed-dose regimens. Pain. 2005;115:254–263.
    1. Punay NC, Couch JR. Antidepressants in the treatment of migraine headache. Curr Pain Headache Rep. 2003;7:51–54.
    1. Storey JR, Calder CS, Hart DE, Potter DL. Topiramate in migraine prevention: a double-blind, placebo-controlled study. Headache. 2001;41:968–975.
    1. Rapoport A, Mauskop A, Diener HC, Schwalen S, Pfeil J. Long-term migraine prevention with topiramate: open-label extension of pivotal trials. Headache. 2006;46:1151–1160.
    1. Afshari D, Rafizadeh S, Rezaei M. A comparative study of the effects of low-dose topiramate versus sodium valproate in migraine prophylaxis. Int J Neurosci. 2012;122:60–68.
    1. Bostani A, Rajabi A, Moradian N, Razazian N, Rezaei M. The effects of cinnarizine versus sodium valproate in migraine prophylaxis. Int J Neurosci. 2013;123:487–493.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj